CANY
KRYS icon

Caxton Associates (New York)’s Krystal Biotech KRYS Stock Holding History

Caxton Associates (New York)’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,621
Closed -$665K – 593
2024
Q2 		$665K Buy
3,621
+2,317
+178% +$389K 0.02% 299
2024
Q1 		$232K Buy
+1,304
New +$181K 0.01% 416

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Associates (New York)'s KRYS Position: Q3 2024 in Review

Caxton Associates (New York) sold out of Krystal Biotech (KRYS) in Q3 2024, closing a stake of 3,621 shares — an estimated $665K sold.

Caxton Associates (New York) first reported a position in KRYS in Q1 2024 and held it in 2 quarters. The position peaked at $665K in Q2 2024. 283 funds tracked by Wall St. Rank hold KRYS as of Q3 2024.

  • Caxton Associates (New York) reported no remaining Krystal Biotech position as of Q3 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 3,621 Krystal Biotech shares in Q3 2024, an estimated $665K.
  • Caxton Associates (New York) first reported a position in Krystal Biotech in Q1 2024 and held it in 2 quarters.
  • Caxton Associates (New York)'s Krystal Biotech position peaked at $665K in Q2 2024.
  • 283 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2024.

Based on Caxton Associates (New York)'s 13F filing for Q3 2024, filed 14 Nov 2024.